Company / Accounts Receivable
NOVAVAX INC Accounts Receivable History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$106.4M
FY2025
5-year range
$82.4M / $455.0M
FY2021-FY2025
Trend
-1.7%
vs FY2024
Sector context
#55 of 115
Health Care
What the data says
At $106M, NOVAVAX INC's accounts receivable ranks #55 of 115 in the Health Care sector. Declined from $297M to $106M over the past 2 years.
Based on SEC 10-K filings.
$106M in FY2025 with a 3-year CAGR of +8.9%.
Declined from $297M to $106M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +8.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#55 of 115 in Health CareTop 48% of 115This company $106.4M Sector average $1.1B
▼
-90.5% below sector average
Key checks
Key Insights
- 3-year CAGR of +8.9%, indicating consistent growth.
- In FY2025, accounts receivable decreased 1.7% year-over-year.
- Ranks #55 out of 115 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.87 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.5%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $106.4M | -1.7% |
| FY2024 | $108.3M | -63.6% |
| FY2023 | $297.2M | +260.8% |
| FY2022 | $82.4M | -81.9% |
| FY2021 | $455.0M | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026